Nisa Investment Advisors LLC decreased its stake in Editas Medicine Inc (NASDAQ:EDIT) by 0.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,810 shares of the company’s stock after selling 500 shares during the period. Nisa Investment Advisors LLC owned about 0.15% of Editas Medicine worth $1,611,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the stock. Blair William & Co. IL grew its stake in shares of Editas Medicine by 14.7% in the third quarter. Blair William & Co. IL now owns 13,300 shares of the company’s stock worth $423,000 after acquiring an additional 1,700 shares during the period. Voya Investment Management LLC grew its stake in shares of Editas Medicine by 13.4% in the second quarter. Voya Investment Management LLC now owns 17,849 shares of the company’s stock worth $640,000 after acquiring an additional 2,110 shares during the period. LPL Financial LLC grew its stake in shares of Editas Medicine by 24.0% in the third quarter. LPL Financial LLC now owns 13,016 shares of the company’s stock worth $414,000 after acquiring an additional 2,520 shares during the period. Swiss National Bank grew its stake in shares of Editas Medicine by 4.4% in the third quarter. Swiss National Bank now owns 61,800 shares of the company’s stock worth $1,966,000 after acquiring an additional 2,600 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in shares of Editas Medicine by 9.9% in the third quarter. Commonwealth Equity Services LLC now owns 29,919 shares of the company’s stock worth $952,000 after acquiring an additional 2,701 shares during the period. 68.54% of the stock is currently owned by institutional investors.
Shares of NASDAQ:EDIT opened at $19.75 on Friday. The company has a current ratio of 13.14, a quick ratio of 13.13 and a debt-to-equity ratio of 0.15. Editas Medicine Inc has a 1-year low of $17.80 and a 1-year high of $45.02. The company has a market cap of $928.95 million, a price-to-earnings ratio of -6.63 and a beta of 2.56.
Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.40. Editas Medicine had a negative net margin of 410.68% and a negative return on equity of 53.15%. The business had revenue of $14.52 million for the quarter, compared to the consensus estimate of $9.83 million. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. The company’s revenue for the quarter was up 131.2% on a year-over-year basis. On average, equities research analysts predict that Editas Medicine Inc will post -2.18 EPS for the current fiscal year.
In other news, CTO Vickesh Myer sold 4,000 shares of the business’s stock in a transaction on Tuesday, November 20th. The shares were sold at an average price of $26.50, for a total value of $106,000.00. Following the transaction, the chief technology officer now owns 2,700 shares of the company’s stock, valued at $71,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Katrine Bosley sold 12,000 shares of the business’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $31.92, for a total transaction of $383,040.00. Following the completion of the sale, the chief executive officer now owns 1,217,066 shares in the company, valued at approximately $38,848,746.72. The disclosure for this sale can be found here. Insiders have sold 61,179 shares of company stock worth $1,623,659 in the last ninety days. Insiders own 5.20% of the company’s stock.
A number of analysts have recently commented on the stock. ValuEngine lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. BidaskClub upgraded shares of Editas Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 4th. Zacks Investment Research raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Tuesday, November 13th. Chardan Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Editas Medicine in a report on Tuesday, January 22nd. Finally, SunTrust Banks reissued a “buy” rating on shares of Editas Medicine in a report on Monday, December 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. Editas Medicine presently has an average rating of “Hold” and an average target price of $42.50.
About Editas Medicine
Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.
Recommended Story: Debt-To-Equity Ratio